Karyopharm Therapeutics Inc. (KPTI) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
30Y Low0.9·High23.8
ROE
N/A
—
5yr avg: N/A
30Y Low-391%·High-42%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KPTI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Karyopharm Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $77M | $80M | $82M | $99M | $278M | $483M | $1.1B | $1.2B | $532M | $440M | $352M |
| Enterprise Value | $250M | $254M | $214M | $224M | $322M | $473M | $1.2B | $1.2B | $516M | $371M | $303M |
| P/E Ratio → | -0.50 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.53 | 0.55 | 0.57 | 0.68 | 1.77 | 2.30 | 10.30 | 29.01 | 17.53 | 274.25 | 2287.93 |
| P/B Ratio | — | — | — | — | — | — | 22.04 | 23.84 | 2.90 | 3.40 | 2.17 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KPTI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.74 | 1.48 | 1.53 | 2.05 | 2.25 | 10.72 | 28.91 | 17.02 | 231.27 | 1965.44 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
KPTI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Karyopharm Therapeutics Inc. earns an operating margin of -62.1%. Operating margins have expanded from -88.7% to -62.1% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 95.9% | 95.9% | 96.6% | 96.7% | 98.4% | 97.5% | 94.1% | -431.9% | -6583.7% | -56353.2% |
| Operating Margin | -62.1% | -62.1% | -82.2% | -88.7% | -90.5% | -46.8% | -159.0% | -462.9% | -593.0% | -8133.2% | -71903.9% |
| Net Profit Margin | -134.2% | -134.2% | -52.6% | -98.0% | -105.2% | -59.1% | -181.6% | -488.1% | -588.1% | -8036.4% | -71153.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -391.3% | -171.4% | -114.1% | -88.4% | -60.8% |
| ROA | -143.7% | -143.7% | -37.8% | -47.8% | -49.8% | -40.1% | -64.6% | -62.7% | -68.4% | -71.5% | -55.4% |
| ROIC | — | — | — | -1229.1% | -391.7% | -2376.0% | -182.3% | -133.0% | -118.2% | -113.2% | -65.8% |
| ROCE | -205.0% | -205.0% | -98.3% | -55.9% | -54.3% | -40.6% | -68.5% | -69.7% | -84.6% | -88.6% | -60.8% |
KPTI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $173M ($234M total debt minus $61M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 2.59 | 2.51 | 0.56 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | 0.89 | -0.08 | -0.08 | -0.53 | -0.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.27 | -3.27 | -1.04 | -4.99 | -5.60 | -3.75 | -6.22 | -11.75 | -70.55 | — | — |
KPTI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.12x means Karyopharm Therapeutics Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.37x to 1.12x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | 1.12 | 1.70 | 3.37 | 5.31 | 3.74 | 4.59 | 6.01 | 7.13 | 3.00 | 7.99 |
| Quick Ratio | 1.08 | 1.08 | 1.64 | 3.32 | 5.25 | 3.68 | 4.55 | 6.00 | 7.13 | 3.00 | 7.99 |
| Cash Ratio | 0.69 | 0.69 | 1.18 | 2.76 | 4.22 | 3.10 | 4.14 | 5.65 | 7.00 | 2.96 | 7.86 |
| Asset Turnover | — | 1.35 | 0.88 | 0.61 | 0.44 | 0.69 | 0.35 | 0.14 | 0.09 | 0.01 | 0.00 |
| Inventory Turnover | 1.47 | 1.47 | 1.27 | 1.62 | 1.23 | 0.83 | 1.02 | 6.96 | — | — | — |
| Days Sales Outstanding | — | 65.42 | 77.32 | 67.39 | 109.42 | 39.14 | 43.50 | 70.17 | — | — | — |
KPTI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Karyopharm Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $8M | $8M | $5M | $5M | $5M | $4M | $4M | $3M | $3M |
Peer Comparison
Compare KPTI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KPTIYou | $77M | -0.5 | — | — | 95.9% | -62.1% | — | — | — |
 PTCT | $7B | 10.2 | 6.8 | 9.3 | 95.9% | 49.5% | — | — | 0.5 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 ADMA | $2B | 13.8 | 9.6 | 69.2 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 TGTX | $8B | 19.2 | 67.4 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 PRTA | $468M | -2.0 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 HALO | $8B | 26.8 | 11.2 | 12.6 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
KPTI — Frequently Asked Questions
Quick answers to the most common questions about buying KPTI stock.
What is Karyopharm Therapeutics Inc.'s P/E ratio?
Karyopharm Therapeutics Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Is KPTI stock overvalued?
Based on historical data, Karyopharm Therapeutics Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Karyopharm Therapeutics Inc.'s profit margins?
Karyopharm Therapeutics Inc. has 95.9% gross margin and -62.1% operating margin.